Evidence map›Paper›PMID 25180583›Full record

ArticlePloS one2014

Revaccination of cattle with bacille Calmette-Guérin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis.

Natalie A Parlane, Dairu Shu, Supatsak Subharat, D Neil Wedlock, Bernd H A Rehm, Geoffrey W de Lisle, Bryce M Buddle

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. B Cell and Antibody Responses in Bovine Tuberculosis.Antibodies (Basel, Switzerland) · 2024
    Review
  3. Safety and Immunogenicity of RecombinantInternational journal of molecular sciences · 2023
    Article
  4. Review
  5. Article
  6. Vaccination of Calves with theAnimals : an open access journal from MDPI · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Tuberculosis vaccine development: from classic to clinical candidates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  14. Review
  15. Review
  16. International journal of microbiology · 2019
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Natalie A ParlaneAgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
Dairu ShuAgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
Supatsak SubharatAgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
D Neil WedlockAgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
Bernd H A RehmInstitute of Fundamental Sciences and MacDiarmid Institute for Advanced Materials and Nanotechnology, Massey University, Palmerston North, New Zealand.
Geoffrey W de LisleAgResearch, National Centre for Biosecurity and Infectious Disease - Wallaceville, Upper Hutt, New Zealand.
Bryce M BuddleAgResearch, Hopkirk Research Institute, Palmerston North, New Zealand.
AgResearch · NZMassey University · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In both humans and animals, controversy exists concerning the duration of protection induced by BCG vaccine against tuberculosis (TB) and whether revaccination enhances protection. A long-term study was undertaken to determine whether BCG-vaccinated calves would be protected against challenge with Mycobacterium bovis 2½ years after vaccination and to determine the effect of revaccination after 2 years. Seventy-nine calves were divided into five groups (n = 15-17 calves/group) with four of the groups vaccinated subcutaneously with 105 CFU of BCG Danish at 2-4 weeks of age and the fifth group serving as non-vaccinated controls. Three of the four BCG-vaccinated groups were revaccinated 2 years after the initial vaccination. One BCG-vaccinated group was revaccinated with BCG. A second group was vaccinated subcutaneously with a TB protein vaccine consisting of biopolyester particles (Biobeads) displaying two mycobacterial proteins, ESAT-6 and Antigen 85A, mixed with an adjuvant. A third group was vaccinated with TB proteins from M. bovis culture filtrate, mixed with an adjuvant. Twenty-three weeks after the BCG revaccination, all animals were challenged endotracheally with virulent M. bovis and a further 13 weeks later, animals were killed and necropsied to determine protection against TB. The BCG-vaccinated animals produced positive tuberculin caudal fold intradermal (15 of 62 animals) and IFN-γ TB test responses (six of 62 animals) at 6 months after vaccination, but not at subsequent time-points compared to the non-vaccinated animals. Calves receiving a single vaccination with BCG vaccine 2½ years prior to challenge were not protected against TB, while those revaccinated with BCG 2 years after the initial vaccination displayed significant reductions in lung and pulmonary lymph node lesion scores compared to the non-vaccinated animals. In contrast, no reduction in lesion scores was observed in the animals revaccinated with the TB protein vaccines with their immune responses biased towards induction of antibody.

Indexed as

AnimalsAntibodies, BacterialBCG VaccineCattleFemaleImmunization, SecondaryInterferon-gammaLungLymph NodesMycobacterium bovisTime FactorsTuberculin TestTuberculosis, BovineTuberculosis VaccinesAntibodies, BacterialBCG VaccineInterferon-gammaTuberculosis Vaccines

Identifiers

PMID25180583
PMCPMC4152303
OpenAlexW1984396388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.